The Company has received funding from private, institutional and corporate investors. Its lead investor is Sanderling Ventures, a prominent life science venture capital fund with $1 billion under management.
Corporate Collaborations and
Theregen is committed to establishing strategic alliances by targeting specific corporate partners. This will enable the Company to expand its resources, strengthen its patent and technology base, and increase its ability to develop and commercialize products in the areas of cardiovascular and vascular health.